On February 13, 2026, Affinity Asset Advisors disclosed a purchase of 61,500 shares of Apogee Therapeutics (NASDAQ:APGE), an estimated $3.87 million trade based on quarterly average pricing.
According to an SEC filing dated February 13, 2026, Affinity Asset Advisors, LLC increased its position in Apogee Therapeutics by 61,500 shares during the fourth quarter of 2025. The estimated transaction value, based on the average closing price for the quarter, was $3.87 million. Meanwhile, the fund’s quarter-end stake rose to 1,234,926 shares, with the value of the position increasing by $46.59 million including both share additions and price appreciation.
Top five holdings after the filing:
NASDAQ: APGE: $93.21 million (6.9% of AUM)
NASDAQ: INSM: $78.32 million (5.8% of AUM)
NASDAQ: ABVX: $68.10 million (5.0% of AUM)
NASDAQ: VTYX: $58.56 million (4.3% of AUM)
NASDAQ: XENE: $56.02 million (4.1% of AUM)
As of February 13, 2026, shares of Apogee Therapeutics were priced at $67.78, up 86.9% over the past year, with 75.14 percentage points of alpha versus the S&P 500.
Metric
Value
Market capitalization
$4 billion
Net income (TTM)
($253.67 million)
Price (as of market close 2/13/26)
$67.78
Apogee Therapeutics develops biologic therapies, including monoclonal antibodies such as APG777 for atopic dermatitis and APG808 for chronic obstructive pulmonary disease, with additional pipeline candidates targeting inflammatory and immunology indications.
The company operates a research-driven biotechnology model focused on advancing proprietary biologics from early-stage development through clinical trials, aiming for regulatory approval and future commercialization.
It targets patients with chronic inflammatory and immunological diseases, with primary customers expected to be healthcare providers, hospitals, and specialty clinics treating these conditions.
Apogee Therapeutics is a clinical-stage biotechnology company specializing in the development of extended half-life monoclonal antibodies for the treatment of atopic dermatitis, COPD, and related inflammatory diseases. The company’s strategy centers on leveraging proprietary biologic platforms to address significant unmet medical needs in immunology. With a focused pipeline and a scalable approach to biologics development, Apogee aims to establish a competitive position in the specialty therapeutics market.
This move has the hallmarks of a high-conviction biotech bet on a name that’s certainly showing some momentum. In the firm’s latest quarterly report, released last month, Apogee CEO Donald Nolan said he was “proud” of the firm’s “disciplined execution” despite a “challenging environment.” The Apogee position now totals 1,234,926 shares valued at $93.21 million, or 6.9% of reportable assets. The holding climbed $46.59 million in value during the period, thanks to a steep ascent throughout the quarter. And with the stock delivering roughly 75 percentage points of alpha versus the S&P 500, this is no small bet.
More broadly, the portfolio is concentrated in clinical-stage biotech names such as Insmed, Abivax, Ventyx, and Xenon, each between 4% and 6% of assets. Apogee now sits at the top of that cluster, suggesting differentiated confidence in its monoclonal antibody pipeline targeting atopic dermatitis and COPD.
Ultimately, long-term investors should remember what drives outcomes here. Clinical data, regulatory milestones, and capital discipline matter more than short-term volatility.
